Solventum vs Steris
SOLV and STE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SOLV and STE compare
Steris is the larger company, worth 1.6 times as much as Solventum ($22.1B against $13.8B).
On earnings, Solventum is cheaper: it trades at 9.9× trailing earnings, against 27.8× for Steris.
Steris grew revenue faster over the last twelve months (8.4% versus −0.93% for Solventum).
Solventum keeps more of each dollar of sales as profit, with a net margin of 17.3% compared with 13.3% at Steris.
Steris pays a dividend yielding 0.86%; Solventum does not pay one.
Steris scores higher on the StockData Score (21 against 14 for Solventum), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SOLV | STE |
|---|---|---|
| Size and price | ||
| Market cap | $13.8B | $22.1B |
| Share price | $81.33 | $227.12 |
| Change, 1 year | 16.6% | −4.1% |
| Change, 5 years | – | 1.1% |
| Beta (5Y) | 0.58 | 0.77 |
| Employees | 10K | 17K |
| StockData Score | ||
| Total score | 14 | 21 (better) |
| Valuation score | 6 (better) | 4 |
| Growth score | 2 | 3 (better) |
| Performance score | 5 (better) | 4 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 9.9× (better) | 27.8× |
| P/S | 1.7× (better) | 3.7× |
| P/B | 2.9× (better) | 3.1× |
| EV/EBITDA | 7.2× (better) | 14.4× |
| P/FCF | – | 23.9× |
| PEG | 2.21 | 0.29 (better) |
| FCF yield | −0.85% | 4.2% (better) |
| Fair value | $185.43 | $255.07 |
| Margin of safety | 56.1% (better) | 11.0% |
| Growth | ||
| Revenue growth (TTM) | −0.93% | 8.4% (better) |
| Revenue growth, 5Y average | – | 13.8% |
| Net income growth (TTM) | 277% (better) | 24.5% |
| EPS growth (TTM) | 277% (better) | 25.5% |
| EPS growth, 5Y average | – | 11.4% |
| Profitability | ||
| Gross margin | 54.7% (better) | 44.4% |
| Operating margin | 25.0% (better) | 18.9% |
| Net margin | 17.3% (better) | 13.3% |
| FCF margin | −1.4% | 15.3% (better) |
| Return on equity | 34.0% (better) | 11.4% |
| Return on invested capital | 17.2% (better) | 9.9% |
| Financial health | ||
| Debt / equity | 1.06 | 0.26 (better) |
| Net debt / EBITDA | 1.81 | 0.86 (better) |
| Interest coverage | – | 18.8× |
| Current ratio | 1.02 | 1.91 (better) |
| Altman Z-score | 2.14 | 5.23 (better) |
| Piotroski F-score | 5 | 9 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.86% |
| Payout ratio | – | 30.7% |
| Years of dividend growth | – | 9 |
| Dividend growth, 5Y average | – | 9.4% |
| Buyback yield | – | 1.5% |
| Shareholder yield | 0.00% | 2.4% (better) |
| Ownership | ||
| Held by institutions | 75.0% | 97.4% |
| Held by insiders | 30.3% | 0.34% |
| Insider net buying, 12 months | $100K (better) | −$9.8M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 4.1% | 2.9% |
Go deeper
- SOLV stock overview
- SOLV income statement
- SOLV valuation and score
- STE stock overview
- STE income statement
- STE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.